Showing 1 - 9 results of 9 for search 'Jeka, S', query time: 0.02s Refine Results
  1. 1
    Dual-energy X-ray absorptiometry – is it the gold standard, or is bone mineral density everything?

    Dual-energy X-ray absorptiometry – is it the gold standard, or is bone mineral density everything? by Paweł Żuchowski, Daniel Jeka

    Published 2024-03-01
    Get full text
    Article
  2. 2
    Immediate application of low-intensity electrical noise reduced responses to visual perturbations during walking in individuals with cerebral palsy

    Immediate application of low-intensity electrical noise reduced responses to visual perturbations during walking in individuals with cerebral palsy by Ashwini Sansare, Maelyn Arcodia, Samuel C. K. Lee, John Jeka, Hendrik Reimann

    Published 2024-01-01
    Get full text
    Article
  3. 3
    Osteoporosis in axial radiographic spondyloarthritis: diagnostic limitations of bone mineral density and the need for comprehensive fracture risk assessment

    Osteoporosis in axial radiographic spondyloarthritis: diagnostic limitations of bone mineral density and the need for comprehensive fracture risk assessment by Paweł Żuchowski, Marta Dura, Daniel Jeka, Rafał Wojciechowski, Maciej Bierwagen, Michał Kułakowski

    Published 2024-12-01
    Get full text
    Article
  4. 4
    Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis

    Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis by Joanna Wielińska, Jerzy Świerkot, Katarzyna Kolossa, Bartosz Bugaj, Monika Chaszczewska-Markowska, Sławomir Jeka, Katarzyna Bogunia-Kubik

    Published 2021-01-01
    Get full text
    Article
  5. 5
    Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

    Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial by Baraliakos, X, Gossec, L, Pournara, E, Jeka, S, Varela, AM, D’Angelo, S, Schulz, B, Rissler, M, Nagar, K, Perella, C, Coates, LC

    Published 2020
    Journal article
  6. 6
    Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance

    Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance by Bogdan Batko, Slawomir Jeka, Piotr Wiland, Agnieszka Zielińska, Maria Stopińska-Polaszewska, Marcin Stajszczyk, Magdalena Kosydar-Piechna, Mary Jane Cadatal, Jose L. Rivas

    Published 2024-07-01
    Get full text
    Article
  7. 7
    Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial

    Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial by Baraliakos, X, Gossec, L, Pournara, E, Jeka, S, Blanco, R, D'Angelo, S, Schett, G, Schulz, B, Rissler, M, Whyms, D, Perella, C, Coates, LC

    Published 2021
    Conference item
  8. 8
    A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

    A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with... by Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, Shengyun Liu, Huaxiang Liu, Malgorzata Miakisz, Jieruo Gu, Lali Kilasonia, Mykola Stanislavchuk, Xiaolei Yang, Yinbo Zhou, Qingfeng Dong, Marian Mitroiu, Janet Addison, Mourad F. Rezk, Xiaofeng Zeng

    Published 2024-09-01
    Get full text
    Article
  9. 9
    Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47

    Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis,... by Edward Keystone, Josef S Smolen, Gerd R Burmester, Slawomir Jeka, Pawel Hrycaj, Janusz Jaworski, Anna Dudek, Artur Racewicz, Agnieszka Zielinska, YunJu Bae, Rafal Wojciechowski, Marek Krogulec, Jakub Trefler, Katarzyna Kolossa, Magdalena Krajewska-Włodarczyk, Piotr Adrian Klimiuk, SungHyun Kim, GoEun Yang, YooBin Jung, JiWoo Hong

    Published 2024-10-01
    Get full text
    Article

Search Tools: